Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group

J. P. Neijt, M. E L van der Burg, J. P. Guastalla, M. George, M. Piccart, J. Vermorken, F. Carnino, N. Rotmensz

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.

Original languageEnglish
Pages (from-to)663-665
Number of pages3
JournalActa Oncologica
Volume28
Issue number5
DOIs
Publication statusPublished - 1989

Keywords

  • Advanced ovarian cancer
  • Mitozolomide
  • Phase II study

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Fingerprint

Dive into the research topics of 'Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group'. Together they form a unique fingerprint.

Cite this